FDA Halts Sarepta’s ELEVIDYS Distribution and Clinical Trials After Three Deaths Linked to Gene Therapy

On July 18, 2025, the U.S. Food and Drug Administration (FDA) took decisive action against Sarepta Therapeutics following the deaths of three individuals who had received the company’s gene therapy…

Continue Reading FDA Halts Sarepta’s ELEVIDYS Distribution and Clinical Trials After Three Deaths Linked to Gene Therapy
Experimental Limb-Girdle Muscular Dystrophy Drug May Have Path to Accelerated Approval
source: shutterstock.com

Experimental Limb-Girdle Muscular Dystrophy Drug May Have Path to Accelerated Approval

According to a story from BioPharma Dive, the drug company BridgeBio has been working on the development of a new treatment for limb-girdle muscular dystrophy, a rare disease. At the…

Continue Reading Experimental Limb-Girdle Muscular Dystrophy Drug May Have Path to Accelerated Approval
New Research on Gene Therapies for Limb-Girdle Muscular Dystrophy 2B
mohamed_hassan / Pixabay

New Research on Gene Therapies for Limb-Girdle Muscular Dystrophy 2B

According to a recent article, Dr. Jyoti K. Jaiswal shared his research pertaining to gene therapies to be used to treat limb-girdle muscular dystrophy 2B (LGMD2B). Limb-Girdle Muscular Dystrophy (LGMD)…

Continue Reading New Research on Gene Therapies for Limb-Girdle Muscular Dystrophy 2B
ICYMI: SRP-9003 Study Shows Positive Results for Treating LGMD Type 2E
27707 / Pixabay

ICYMI: SRP-9003 Study Shows Positive Results for Treating LGMD Type 2E

  In a recent press release, biotechnology company Sarepta Therapeutics announced positive findings from their clinical trial studying SRP-9003 as a treatment for limb-girdle muscular dystrophy (LGMD) type 2E. This…

Continue Reading ICYMI: SRP-9003 Study Shows Positive Results for Treating LGMD Type 2E
New Data Gives Hope for a Limb-Girdle Muscular Dystrophy Gene Therapy
source: pixabay.com

New Data Gives Hope for a Limb-Girdle Muscular Dystrophy Gene Therapy

According to a story from BioPharma Dive, the drug company Sarepta Therapeutics is pushing forward with its plans to develop a gene therapy for limb-girdle muscular dystrophy (LGMD). The company…

Continue Reading New Data Gives Hope for a Limb-Girdle Muscular Dystrophy Gene Therapy
AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials
source: pixabay.com

AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials

AskBio Asklepios BioPharmaceuticals (AskBio) was first founded in 2001. It is based out of North Carolina.  This company is dedicated to the research of gene therapies as potential therapeutic options…

Continue Reading AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials

Ribitol Could Benefit Patients With Rare Limb Girdle Muscular Dystrophy and Related Diseases

A recent study published in the journal Nature Communications highlights a potential therapy for the treatment of muscular dytrophies and other diseases linked to mutations of the FKRP gene. In the study, the…

Continue Reading Ribitol Could Benefit Patients With Rare Limb Girdle Muscular Dystrophy and Related Diseases
Treatment for Type 2E Limb Girdle Muscular Dystrophy Gets Rare Pediatric Drug Designation
source: pixabay.com

Treatment for Type 2E Limb Girdle Muscular Dystrophy Gets Rare Pediatric Drug Designation

According to a story from Business Wire, the gene therapy company Myonexus Therapeutics announced that the U.S. FDA has given Rare Pediatric Disease Designation for its gene therapy candidate MYO-101.…

Continue Reading Treatment for Type 2E Limb Girdle Muscular Dystrophy Gets Rare Pediatric Drug Designation